Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O14813
UPID:
PHX2A_HUMAN
Alternative names:
ARIX1 homeodomain protein; Aristaless homeobox protein homolog; Paired-like homeobox 2A
Alternative UPACC:
O14813; A8K3N0; Q8IVZ2
Background:
Paired mesoderm homeobox protein 2A, also known as ARIX1 homeodomain protein, Aristaless homeobox protein homolog, and Paired-like homeobox 2A, plays a crucial role in the regulation of catecholamine biosynthetic genes. Acting as a transcription activator, it is pivotal in maintaining the noradrenergic phenotype, which is essential for the proper functioning of the nervous system.
Therapeutic significance:
The protein's involvement in congenital fibrosis of extraocular muscles type 2, a disorder characterized by restrictive ophthalmoplegia, highlights its clinical significance. Understanding the role of Paired mesoderm homeobox protein 2A could open doors to potential therapeutic strategies for this and related ocular motility disorders.